Sarah Dandou, Julie A Vendrell, Jérôme Solassol, Baptiste Louveau, Céleste Lebbé, Samia Mourah, Florian Rambow, Eric Richard, Stanislas Du Manoir, Alain Mangé, Peter J Coopman, Ovidiu Radulescu, Romain M Larive
{"title":"MelanoDB: MAPK抑制剂治疗晚期黑色素瘤患者的临床和分子特征数据集。","authors":"Sarah Dandou, Julie A Vendrell, Jérôme Solassol, Baptiste Louveau, Céleste Lebbé, Samia Mourah, Florian Rambow, Eric Richard, Stanislas Du Manoir, Alain Mangé, Peter J Coopman, Ovidiu Radulescu, Romain M Larive","doi":"10.1038/s41597-025-05291-3","DOIUrl":null,"url":null,"abstract":"<p><p>MAPK inhibitors (MAPKi) have revolutionized the treatment of patients with advanced melanoma. However, primary and acquired resistance mechanisms limit their efficacy. Predicting MAPKi response from the tumor baseline features remains challenging due to the limited size of patient cohorts. Therefore, we collected data from nine different patient cohorts (total n = 417 patients with advanced melanoma treated with MAPKi) to identify clinical and molecular features. Our curated dataset, named MelanoDB, includes whole or partial exome sequencing data for 191 patients, copy number alteration information for 66 patients, and gene expression data for 132 patients. We provide a web application to explore the integrated dataset and data distribution across the collected studies, and we share this dataset with the scientific community according to the Findable, Accessible, Interoperable, Reusable (FAIR) principles.</p>","PeriodicalId":21597,"journal":{"name":"Scientific Data","volume":"12 1","pages":"1144"},"PeriodicalIF":6.9000,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227540/pdf/","citationCount":"0","resultStr":"{\"title\":\"MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors.\",\"authors\":\"Sarah Dandou, Julie A Vendrell, Jérôme Solassol, Baptiste Louveau, Céleste Lebbé, Samia Mourah, Florian Rambow, Eric Richard, Stanislas Du Manoir, Alain Mangé, Peter J Coopman, Ovidiu Radulescu, Romain M Larive\",\"doi\":\"10.1038/s41597-025-05291-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>MAPK inhibitors (MAPKi) have revolutionized the treatment of patients with advanced melanoma. However, primary and acquired resistance mechanisms limit their efficacy. Predicting MAPKi response from the tumor baseline features remains challenging due to the limited size of patient cohorts. Therefore, we collected data from nine different patient cohorts (total n = 417 patients with advanced melanoma treated with MAPKi) to identify clinical and molecular features. Our curated dataset, named MelanoDB, includes whole or partial exome sequencing data for 191 patients, copy number alteration information for 66 patients, and gene expression data for 132 patients. We provide a web application to explore the integrated dataset and data distribution across the collected studies, and we share this dataset with the scientific community according to the Findable, Accessible, Interoperable, Reusable (FAIR) principles.</p>\",\"PeriodicalId\":21597,\"journal\":{\"name\":\"Scientific Data\",\"volume\":\"12 1\",\"pages\":\"1144\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2025-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227540/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scientific Data\",\"FirstCategoryId\":\"103\",\"ListUrlMain\":\"https://doi.org/10.1038/s41597-025-05291-3\",\"RegionNum\":2,\"RegionCategory\":\"综合性期刊\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientific Data","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41597-025-05291-3","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors.
MAPK inhibitors (MAPKi) have revolutionized the treatment of patients with advanced melanoma. However, primary and acquired resistance mechanisms limit their efficacy. Predicting MAPKi response from the tumor baseline features remains challenging due to the limited size of patient cohorts. Therefore, we collected data from nine different patient cohorts (total n = 417 patients with advanced melanoma treated with MAPKi) to identify clinical and molecular features. Our curated dataset, named MelanoDB, includes whole or partial exome sequencing data for 191 patients, copy number alteration information for 66 patients, and gene expression data for 132 patients. We provide a web application to explore the integrated dataset and data distribution across the collected studies, and we share this dataset with the scientific community according to the Findable, Accessible, Interoperable, Reusable (FAIR) principles.
期刊介绍：
Scientific Data is an open-access journal focused on data, publishing descriptions of research datasets and articles on data sharing across natural sciences, medicine, engineering, and social sciences. Its goal is to enhance the sharing and reuse of scientific data, encourage broader data sharing, and acknowledge those who share their data.
The journal primarily publishes Data Descriptors, which offer detailed descriptions of research datasets, including data collection methods and technical analyses validating data quality. These descriptors aim to facilitate data reuse rather than testing hypotheses or presenting new interpretations, methods, or in-depth analyses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
